Identification of microRNA-451a as a Novel Circulating Biomarker for Colorectal Cancer Diagnosis

Abstract

Background. Colorectal cancer (CRC) is one of the leading causes of cancer death worldwide. Successful treatment of CRC relies on accurate early diagnosis, which is currently a challenge due to its complexity and personalized pathologies. Thus, novel molecular biomarkers are needed for early CRC detection. Methods. Gene and microRNA microarray profiling of CRC tissues and miRNA-seq data were analyzed. Candidate microRNA biomarkers were predicted using both CRC-specific network and miRNA-BD tool. Validation analyses were carried out to interrogate the identified candidate CRC biomarkers. Results. We identified miR-451a as a potential early CRC biomarker circulating in patient’s serum. The dysregulation of miR-451a was revealed both in primary tumors and in patients’ sera. Downstream analysis validated the tumor suppressor role of miR-451a and high sensitivity of miR-451a in CRC patients, further confirming its potential role as CRC circulation biomarker. Conclusion. The miR-451a is a potential circulating biomarker for early CRC diagnosis.

A two-microRNA signature predicts the progression of male thyroid cancer

“…The molecule miR-451a has been studied in many types of cancer such as stomach cancer, hepatocellular carcinoma, bladder cancer, colorectal cancer, and basal cell carcinoma. Several studies have suggested that a low expression level of miR-451a positively correlates with the metastatic ability and invasiveness of cancer cells [ 23 , 24 , 25 , 26 , 27 ]. Some studies suggest that miR-451a can be used as a biological marker to predict the risk of recurrence [ 23 , 24 ].…”

“…Several studies have suggested that a low expression level of miR-451a positively correlates with the metastatic ability and invasiveness of cancer cells [ 23 , 24 , 25 , 26 , 27 ]. Some studies suggest that miR-451a can be used as a biological marker to predict the risk of recurrence [ 23 , 24 ]. In the field of TC research, experimental data from multiple cell types have confirmed that miR-451a could suppress tumour cell proliferation and invasion by targeting PSMB8 and ZEB1 [ 28 , 29 ].…”

Evaluation of serum miRNAs expression in frail and robust subjects undergoing multicomponent exercise protocol (VIVIFRAIL)

“…Notably, both findings indicate a possible role played by this miRNA in the age-associated decline of muscle mass and function characteristic of frailty and sarcopenia. miR-451a is also present in serum, where it can be found either inside vesicles or as non-vesicle associated protein (miRNA-protein, or miRNA-lipid/lipoprotein complexes) [40,[45][46][47][48]. Importantly, when inside vesicles Table 2 Serum miRNAs expression in frail subjects and in robust subjects before and after intervention.…”

Specific Plasma MicroRNA Signatures in Predicting and Confirming Crohn's Disease Recurrence: Role and Pathogenic Implications

“…Although miR-451 has not previously been described in the context of IBD, this study revealed it to be permanently increased. The role of miR-451 in cancer has been reported to function by repressing colorectal cancer by inhibiting tumor growth and IL6R expression ( 42 ) and the PI3K/AKT/mTOR signaling pathway ( 43 ), being dysregulated in primary colorectal tumors and in patients' sera ( 44 ). It therefore seems that this miRNA could have opposite functions to those of miR-15b-5p, and a compensatory balance between the 2 miRNAs is probably a biological target of the cells to prevent recurrence, although this hypothesis needs further investigation.…”

“…Increased miR-125b-5p levels have been observed when CD4+ T-cell differentiation is inhibited, mainly by targeting interferon-gamma, interleukin-2, and interleukin-10 ( 44 ). This miRNA has also been associated with the inhibition of B-cell activation, the promotion of macrophage activation, and the induction of apoptosis or proliferation through the modulation of p53 expression ( 49 ).…”